136results about How to "Efficient administration" patented technology

The instant invention describes methods of separating or preferentially synthesizing dimers which are linked via at least one interchain disulfide linkage from dimers which are not linked via at least one interchain disulfide linkage from a mixture comprising the two types of polypeptide dimers. These forms can be separated from each other using hydrophobic interaction chromatography. In addition, the invention pertains to connecting peptides that result in the preferential biosynthesis of dimers that are linked via at least one interchain disulfide linkage or that are not linked via at least one interchain disulfide linkage. The invention also pertains to compositions in which a majority of the dimers are linked via at least one interchain disulfide linkage or are not linked via at least one interchain disulfide linkage. The invention still further pertains to novel binding molecules, e.g., comprising connecting peptides of the invention.

A method and system for enabling wireless devices distributed throughout an enterprise to be efficiently initialized for secure communications. The method and system utilize well known public key cryptography and machine unique identifiers to establish a secure channel and initialize the wireless devices.

An optical fiber enclosure system includes a plurality of integrated optical connector and coupler assemblies. The first optic coupler is integrated adjacent to the ferrule in the connector. In a preferred embodiment, the integrated optical connector coupler is constructed in a compact package such that when installed in the optical fiber enclosure no part of the coupler connector assembly protrudes beyond the footprint of the fiber enclosure and yet maintains an industry recommended minimum bend radius of 1.5 inches on the output cable ports thus allowing the fiber enclosure front panel to close without impinging on the cables of the assembly.

A method and apparatus intuitively to administer all components of a networked computer system by use of real multi-dimensional views of any component or any set of components, including components related to a specific business interest, and with customizable and fully extensible functionality, across heterogenous platforms and applications. Navigation and configuration tools are provided, with an intelligent cursor, to travel to and address any component part thereof, or subset of components, with status and abnormalities identified, monitored and controlled, and by hierarchical filtration, and aggregation correlation with asynchronous notification. Graphical presentation tools are also provided employing an enhanced zooming graphical display.

A centralized dispute resolution system for use in commercial credit or debit card transactions. The inventive system utilizes a common data storage, interfaces, processes, procedures, rules, and other elements of a dispute resolution system that are made available to cardholders, merchants, card issuers, payment processors, and other parties that may be involved in a dispute or in a process intended to resolve a dispute. The system may be implemented using a client-server architecture with communication between clients and one or more server elements provided by a communications network.

A method for backing up data in a plurality of computers connected via a network. The method includes forming partnerships between the plurality of computers such that each computer in a partnership commits under agreements to help backup the data of its partners. The method further includes periodically verifying that previously backed up data is being retained by the computers committed to act as backup partners in accordance with the agreements. In another embodiment, the method provides a distributed cooperative backing up of data in a system that includes a loose confederation of computers connected via a network. In this embodiment the method includes selecting computers as potential backup partners from among the loose confederation of computers connected via the network based on predetermined criteria, and negotiating a reciprocal backup partnership agreement between the computers based on predetermined requirements, including backup requirements. Once the negotiations are complete and the agreements are made, the method proceeds to form partnerships between the computers. The computers become backup partners by agreeing to cooperatively provide backup services to each other so that a distributed cooperative backing up of data can be administered in the absence of central control. The method further includes periodically backing up data at the backup partners, where the data being backed up is encoded. The method also includes periodically verifying that previously backed up data is retained by the backup partners. Another aspect of the invention is a distributed cooperative backup system that includes a network and a loose confederation of computers connected via the network. A plurality of computers from among the loose confederation of computers is configured for distributed cooperative backing up of data and for functioning as backup partners. Each computer of the plurality of computers has a storage that can be used for providing reciprocal backup services. Each computer of the plurality of computers respectively also has a computer readable medium embodying computer program code configured to cause the computer to perform functions comparable to the method steps as described above.

A method of administering parenterally, particularly intramuscularly, glutamine and cystine and glycine plus selenium; or lactalbumin plus selenium; or lactalbumin and glutamine and cystine and glycine plus selenium, through a long-acting pharmaceutically acceptable carrier to a patient. The method comprises injecting a mixture of glutamine, cystine, glycine, lactalbumin and selenium in order to maintain the mixture systemically or locally for a sufficient time period so as to maintain blood levels of glutathione within an improved therapeutic range.

The instant invention describes methods of separating or preferentially synthesizing dimers which are linked via at least one interchain disulfide linkage from dimers which are not linked via at least one interchain disulfide linkage from a mixture comprising the two types of polypeptide dimers. These forms can be separated from each other using hydrophobic interaction chromatography. In addition, the invention pertains to connecting peptides that result in the preferential biosynthesis of dimers that are linked via at least one interchain disulfide linkage or that are not linked via at least one interchain disulfide linkage. The invention also pertains to compositions in which a majority of the dimers are linked via at least one interchain disulfide linkage or are not linked via at least one interchain disulfide linkage. The invention still further pertains to novel binding molecules, e.g., comprising connecting peptides of the invention.

A method for automatically changing a version of a client agent for a non-administrative user account without rebooting the user's machine uses a service having installation privileges. The service executes on the client and installs a client agent. The client agent communicates with a network appliance. The client agent detects a difference between its version and a version of the client agent identified by the network appliance. The agent signals the service that it has detected the difference and, in response, the service executes an installation program that installs, without rebooting the client, the version of the client agent identified by the appliance. A corresponding system is also described.

A method and system to manipulate network objects by using Internet authoring, collaboration and versioning tools is described. The method includes: receiving a request for a manipulation of a first network object from a requesting user; verifying a first set of authorization information; translating a logical address of the first network object to a physical file system path; checking a local file system for validity and authorization for the requesting user including determining whether the first network object is a first network object; verifying a username and a password for the requesting user; returning a first error message if requesting user is unauthorized to access the first network object; determining an object type for the first network object; and sending a response to the requesting user. The method can also include verifying that the first network object is found and returning a second error message if the first network object is not found. The first network object can be user object and the request can be to assign new rights to the user object. The new rights for the user can also be for another network object. The new rights can be assigned by dragging and dropping the user object on another network object by the use of interactive computer screen.

The present invention relates to scaffolds which can be used as medical devices for guided tissue regeneration and repair, in particular the invention is directed to a scaffold comprising fibers having a mean fiber diameter of between from about 1.2 to 4.0 microns, wherein the fibers comprise a glycolide. The invention further relates to the use of the scaffolds for the selective capture of cell populations for a cell source material.

A fault localization apparatus for an optical line in a wavelength division multiplexed passive optical network is disclosed. The apparatus can detect light loss and fault positions as a channel exhibiting an abnormal receiving state of signals received by each of the upstream receivers is checked, and a monitoring optical signal is used, in which the monitoring optical signal is generated as a pulse is inputted to a light source of the downstream transmitter corresponding to the channel showing such an abnormal receiving state. The apparatus according to the present invention can detect fault positions of optical lines between the central office and the remote nodes and between the remote nodes and the optical network units, since the light source of downstream channel in which faults occur is used as a monitoring light source. The apparatus according to the present invention can be cost-effectively implemented.

A packaging utility is created that can in turn create a deployment archive (DAR) file containing the data required to install a Web service application, comprising, for example, portlets for creating Web pages for the Web service's user interface, UDDI entries, executable programs, and application-wide properties. The application-wide properties may comprise elements to be used in connection with one or more Web services, for example, encryption levels, service levels, timeouts, and number of retries. For administration efficiency the application-wide properties may be applied according to hierarchies, for example from groupings of Web services to individual Web services and from organizations of users to individual users. An unpackaging tool is created to unpackage and install the DAR file on a target environment. A configuration set is employed by the unpackaging tool to determine where the elements of the Web service application are to be installed on the target environment.

Methods of treating or suppressing oxidative stress diseases and symptoms related to oxidative stress affecting normal electron flow in the cells or caused by reactive oxygen species with redox-active therapeutics. Use of redox-active therapeutics for the reduction, suppression or treatment of oxidative stress induced by chemical agents such as contrast agents and other nephrotoxic agents, by radiation exposure, and by disruptions in the transport of oxygen to tissues, is disclosed.

The present invention relates to a device, method, system and kit for receiving effluent from an individual. In an alternative embodiment, the present invention is directed to a device, method, system and kit for collecting effluent from an individual during a medical or diagnostic procedure including but not limited to, imaging or viewing one or more sections of an individual's gastrointestinal tract. In another alternative embodiment, the effluent is collected in a hollow area in order to prevent the effluent form contaminating a component, device or apparatus used in connection with the medical or diagnostic procedure.

A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.

An apparatus and method for managing and transporting virtual disks over a network to networked stations is disclosed. The apparatus comprises a data storage subsystem and a data processor connected thereto via a network. The data processor includes a virtual disk interface controller to interface with the storage subsystem in handling the input and output for the storage subsystem. The storage subsystem manages a pool of storage blocks in the form of a plurality of virtual disk images and transports the virtual disk images over the network to the virtual disk interface controller. A virtual disk image is emulated as a virtual disk by the virtual disk interface controller and presented to the data processor. The architecture for management and delivery of disk images and the data structure for maintenance of disk images facilitate software deployment and installation onto the networked diskless computers enable highly efficient system administration on the whole network to maximize the network availability.

Data processing system for patient data. The invention refers to a data processing system for the processing of patient data, which includes person identifying data of a respective patient and corresponding health data (GD), with a central system (3), which includes a database (4) storing the health data, and with terminal devices (1), which are connected with the central station for the request of health data from the database and / or for the input of health data into the central database. According to the invention, health data is stored in the central database without assignment to person identifying data, a data record identification code (DIC) being assigned to a health data set of a respective patient, where a retrieval of the health data set necessitates the input of the corresponding data record identification code. The invention can be used e.g. for a system managing patient data records.

The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.

It is intended to provide a transdermal drug administration apparatus having microneedles, which is capable of piercing the skin by a simple procedure in the transdermal administration of a biologically active substance (drug) and allows rapid absorption of the biologically active substance. The present apparatus comprises a microneedle device (50) comprising a microneedle substrate (53) having a plurality of microneedles (51) capable of piercing the skin, an absorbent (11) disposed thereon, the absorbent (11) comprising a material capable of absorbing a liquid, and a dissolving solution reservoir (18) disposed on the absorbent (11), the dissolving solution reservoir (18) containing a dissolving solution (16) for dissolving a drug and being capable of disrupting a diaphragm (20) provided the dissolving solution reservoir (18) and the absorbent (11) by pressing. A coating containing a dry drug is disposed on the microneedles (51) and / or the microneedle substrate (53).

The instant invention describes novel multispecific binding molecules comprising synthetic connecting peptides. The synthetic connecting peptides result in the preferential synthesis of multispecific binding molecules comprising polypeptide chains that are linked via at least one interchain disulfide linkage. In addition, the invention pertains to compositions in which a majority of the multispecific binding molecules comprising polypeptide chain that are linked via at least one interchain disulfide linkage or are not linked via at least one intrachain disulfide linkage. In a specific embodiment, the invention pertains to compositions comprising multispecific dimeric binding molecules said molecules comprising at least a first binding site specific for a tumor necrosis factor (TNF) receptor or a ligand of a TNF receptor family member and at least a second binding site; and at least two polypeptide chains comprising at least one heavy chain portion and a synthetic connecting peptide; wherein greater than about 50% of the dimers comprise polypeptide chains that are linked via at least one interchain disulfide linkage.

It is intended to provide a transdermal drug administration apparatus having microneedles, which is capable of piercing the skin by a simple procedure in the transdermal administration of a biologically active substance (drug) and allows rapid absorption of the biologically active substance. The present apparatus comprises a microneedle device (50) comprising a microneedle substrate (53) having a plurality of microneedles (51) capable of piercing the skin, an absorbent (11) disposed thereon, the absorbent (11) comprising a material capable of absorbing a liquid, and a dissolving solution reservoir (18) disposed on the absorbent (11), the dissolving solution reservoir (18) containing a dissolving solution (16) for dissolving a drug and being capable of disrupting a diaphragm (20) provided the dissolving solution reservoir (18) and the absorbent (11) by pressing. A coating containing a dry drug is disposed on the microneedles (51) and / or the microneedle substrate (53).

A method of treating telangiectasia in a human in need thereof comprising administering to said human a tetracycline compound in an amount that is effective to treat telangiectasia, but has substantially no antibiotic activity.

Stable formulations of an active pharmaceutical agent suitable for oral spray administration for absorption by the oral mucosa and related methods of preparation and administration of active pharmaceutical agent formulations are provided. Preferred embodiments of the invention provide formulations comprising an active pharmaceutical agent, a solvent, a buffer, and a viscosity modifying agent, wherein when a unit dose volume of about 25 to 400 mcL of the oral spray composition is sprayed, the spray has a median particle size diameter of about 40 to about 100 microns.

Systems and methods for managing license privileges associated with software offered for an evaluation period are provided. Methods according to the present invention may include installing an application program on a user terminal; transmitting license information necessary to operate the application program from the user terminal to a license management server; storing the license information in a database; monitoring the license information; and disabling the application program when the license information is not current or has expired. Systems according to the present invention may include a user terminal on which an application program is installed; a license management server coupled to the user terminal through a network; and a license monitor that monitors the application program and the license database. The license management server may include a database of license policies for authorizing the use of at least one application program.

The present invention relates to a process for ameliorating or preventing diseases that are caused, in part, by an increased level of, and / or an abnormal responsivity to, interferon. Alzheimer's disease, HIV infection, Down syndrome, transplant rejection, autoimmune disease, and infant encephalitis are examples of such diseases. Specifically, the invention provides a method for treating subjects suffering from, or at risk for, such diseases by the administration of a pharmacological preparation of interferon binding proteins of mammalian and / or viral origin that antagonize interferon's action. This invention comprises compositions of interferon binding proteins that can inhibit the activity of interferon gamma plus interferon alpha such compositions along with their method of production and modification being described herein.

The instant invention describes methods of separating or preferentially synthesizing dimers which are linked via at least one interchain disulfide linkage from dimers which are not linked via at least one interchain disulfide linkage from a mixture comprising the two types of polypeptide dimers. These forms can be separated from each other using hydrophobic interaction chromatography. In addition, the invention pertains to connecting peptides that result in the preferential biosynthesis of dimers that are linked via at least one interchain disulfide linkage or that are not linked via at least one interchain disulfide linkage. The invention also pertains to compositions in which a majority of the dimers are linked via at least one interchain disulfide linkage or are not linked via at least one interchain disulfide linkage. The invention still further pertains to novel binding molecules, e.g., comprising connecting peptides of the invention.

The invention features methods and compositions for diagnosis and treatment of conditions associated with decreased nitric oxide bioavailability, such as a condition associated with elevated arginase activity, using an arginine- and / or arginase-inhibitor based therapy, which therapies include administration of arginine or an arginase inhibitor, either alone or in combination. The invention also contemplates administration of magnesium with arginine, an arginase inhibitor, or with arginine-arginase inhibitor combination therapy. The invention also features methods and compositions for diagnosis, including prognosis, of conditions associated with arginase activity by assessing the ratio of arginine to ornithine in samples from a subject.

Polypeptide and polynucleotide vaccines effective to treat or prevent infection of a mammal, such as a dog, a cat, or a human, by a protozoan. Methods of treatment and prevention are also provided, including therapeutic administration of the vaccine to an infected mammal to prevent progression of infection to a chronic debilitating disease state. Preferred embodiments of the polynucleotide vaccine contain nucleotide coding regions that encode polypeptides that are surface-associated or secreted by T. cruzi. Optionally the efficacy of the polynucleotide vaccine is increased by inclusion of a nucleotide coding region encoding a cytokine. Preferred embodiments of the polypeptide vaccine include immunogenic peptides that contain membrane transducing sequences that allow the polypeptides to translocate across a mammalian cell membrane.

The present invention provides an iontophoresis device with high administration efficient of a drug. An iontophoresis device, including an active electrode structure including: an electrode to which a positive electrical potential is applied; a drug holding part for holding a drug solution containing positively charged drug ions, the drug holding part being placed on a front side of the electrode; a cellulose-based resin film placed on a front side of the drug holding part or a complex film composed of a cation exchange membrane and a cellulose-based resin film placed on a front side of the cation exchange membrane, the complex film being placed on a front side of the drug holding part, in which the drug ions are administered through the cellulose-based resin film.